Who are Arbutyne's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adenocard, Adenovite, Tinosorb S, Regadenoson, Regadenoson; Optison, trabodenoson 4.5% BID.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arbutin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Arbutyne — Competitive Intelligence Brief

Arbutyne (ARBUTIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adenosine Receptor Agonist [EPC]. Area: Dermatology.

marketed Adenosine Receptor Agonist [EPC] Tyrosinase, Polyphenol oxidase 2, Tyrosinase Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Arbutyne (ARBUTIN).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Arbutyne TARGET	ARBUTIN		marketed	Adenosine Receptor Agonist [EPC]	Tyrosinase, Polyphenol oxidase 2, Tyrosinase
Adenocard	ADENOSINE	Astellas Pharma	marketed	Adenosine Receptor Agonist [EPC]	Adenosine receptor A3	1989-01-01
Adenovite	ADENOSINE PHOSPHATE		marketed	Adenosine Receptor Agonist	Proto-oncogene tyrosine-protein kinase Src
Tinosorb S	BEMOTRIZINOL		marketed	Adenosine Receptor Agonist [EPC]
Regadenoson	Regadenoson	Pfizer Inc.	marketed	Adenosine receptor agonist	A2A adenosine receptor
Regadenoson; Optison	Regadenoson; Optison	University of Nebraska	phase 3	adenosine receptor agonist	A2A receptor
trabodenoson 4.5% BID	trabodenoson 4.5% BID	Inotek Pharmaceuticals Corporation	phase 3	Adenosine receptor agonist	A1 adenosine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adenosine Receptor Agonist [EPC] class)

· 2 drugs in this class
Astellas Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arbutyne — Competitive Intelligence Brief. https://druglandscape.com/ci/arbutin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab